Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02493257 · ClinicalTrials.gov registry record · Phase 2
Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
A Phase 2 study of Nonallergic Irritant Rhinitis, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT02493257: Completed Phase 2 study of Nonallergic Irritant Rhinitis, sponsored by The University of Texas Health Science Center, Houston.
NCT02493257 is a Phase 2 study of Nonallergic Irritant Rhinitis that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02493257, a Phase 2 study of Nonallergic Irritant Rhinitis, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study seeks to investigate the effect of intranasal capsaicin treatment in patient with Non-allergic irritant rhinitis (NAIR), as well as evaluate optical rhinometry (ORM) as a means to quantify symptomatic improvement in NAIR patients during and after treatment.
Primary Outcome
The Total Symptom Score (TSS) uses a visual analog scale (VAS) to assess typical nasal symptoms of non-allergic rhinitis (NAR), including sneezing, nasal irritation, nasal obstruction, and nasal congestion. The TSS is based on a commonly used rhinitis rating system recommended by the FDA for clinical trial studies on non-allergic rhinitis. 4 symptoms (sneezing, nasal irritation, nasal obstruction, and nasal congestion) are rated on a VAS ranging from 0 (none, no distress) to 10 (agonizing, unbea
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Capsaicin
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-08-02 |
| Phase | Phase 2 |
What the finished NCT02493257 record still lists
NCT02493257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Nonallergic Irritant Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02493257 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02493257 about?
NCT02493257 is a clinical study titled "Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis". The proposed study seeks to investigate the effect of intranasal capsaicin treatment in patient with Non-allergic irritant rhinitis (NAIR), as well as evaluate optical rhinometry (ORM) as a means to quantify symptomatic improvement in NAIR patients during and after treatment.
What is the current status of trial NCT02493257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-10. Estimated completion is 2019-08-02.
What conditions does trial NCT02493257 study?
This clinical trial studies the following conditions: Nonallergic Irritant Rhinitis.
What interventions are being tested in trial NCT02493257?
The interventions under investigation include: Placebo (DRUG), Capsaicin (DRUG).
Who is sponsoring clinical trial NCT02493257?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02493257 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02493257's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia